SCHEMBL1285274

SCHEMBL1285274

O=C(O)C=Cc1ccc(F)c(F)c1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.58
ALDH1A1 P00352 1/20 0.50
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA4 P22748 2/20 0.46
NFKB1 P19838 1/20 0.46
TDO2 P48775 1/20 0.42
HCAR2 Q8TDS4 2/20 0.42
HDAC3 O15379 1/20 0.42
TNKS O95271 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1285273 1.00 MIF (0.58) MIFALDH1A1CA1CA2CA4
SCHEMBL29462469 1.00 MIF (0.58) MIFALDH1A1CA1CA2CA4
SCHEMBL2260892 0.85 MIF (0.59) MIFALDH1A1CA1CA2CA4
SCHEMBL3797426 0.85 MIF (0.59) MIFALDH1A1CA1CA2CA4
SCHEMBL2260886 0.85 MIF (0.59) MIFALDH1A1CA1CA2CA4
SCHEMBL3797420 0.85 MIF (0.59) MIFALDH1A1CA1CA2CA4
SCHEMBL585286 0.83 MIF (0.53) MIFALDH1A1CA1CA2CA4
SCHEMBL585287 0.83 MIF (0.53) MIFALDH1A1CA1CA2CA4
SCHEMBL8055896 0.83 MIF (0.53) MIFALDH1A1CA1CA2CA4
SCHEMBL8055895 0.83 MIF (0.53) MIFALDH1A1CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
CN-110993948-A Battery electrode binder 孙爱芬 2020-04-10 CN claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 US claimed
US-9217012-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-12-22 US claimed
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) 2012-04-12 US claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 WO claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 US claimed
EP-1747059-A1 PERVAPORATION COMPOSITE MEMBRANES McMaster University (CA) 2007-01-31 EP claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-20060000778-A1 high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers MCMASTER UNIVERSITY (CA) 2006-01-05 US claimed
WO-2005102503-A1 PERVAPORATION COMPOSITE MEMBRANES MCMASTER UNIVERSITY (CA) 2005-11-03 WO claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
US-12551555-B2 Compositions and methods for potentiating immune activity KUMQUAT BIOSCIENCES INC. (US) 2026-02-17 US disclosed
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP disclosed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO disclosed
CN-114230519-B Pleuromutilin cinnamate compounds with drug-resistant bacteria resisting activity, and synthetic method and application thereof 西咸新区沣厚原创医药科技有限公司 2024-06-04 CN disclosed
CN-114591255-B Pleuromutilin derivative containing 1,2, 4-triazole acrylamide side chain and preparation method and application thereof 西安康远晟生物医药科技有限公司 2024-04-16 CN disclosed
US-20230044323-A1 COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY KUMQUAT BIOSCIENCES INC. 2023-02-09 US disclosed
EP-4073242-A1 COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY Kumquat Biosciences Inc. (US) 2022-10-19 EP disclosed
CN-115103907-A Compositions and methods for enhancing immune activity 金橘生物科技公司 2022-09-23 CN disclosed
CN-114230519-A Pleuromutilin cinnamate compounds with drug-resistant bacterium resisting activity and synthesis method and application thereof 陕西科技大学 2022-03-25 CN disclosed
WO-2021119554-A1 COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY KUMQUAT BIOSCIENCES INC. (US) 2021-06-17 WO disclosed
CN-110993948-A Battery electrode binder 孙爱芬 2020-04-10 CN disclosed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US disclosed
EP-2226192-B1 DRYING SUBSTANCES, PREPARATION AND USE THEREOF ORIDION MEDICAL 1987 LTD (IL) 2016-08-31 EP disclosed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 US disclosed
US-9340574-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-05-17 US disclosed
EP-2226116-B1 Drying tube, preparation and use thereof ORIDION MEDICAL 1987 LTD (IL) 2016-04-20 EP disclosed
US-9217012-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-12-22 US disclosed
US-20150283519-A1 DRYING SUBSTANCES, PREPARATION AND USE THEREOF ORIDION MEDICAL 1987 LTD. (IL) 2015-10-08 US disclosed
US-9150510-B2 Amino acid derivative NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2015-10-06 US disclosed
US-20150239931-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION 2015-08-27 US disclosed
US-9090766-B2 Drying substances, preparation and use thereof ORIDION MEDICAL 1987 LTD. (IL) 2015-07-28 US disclosed
US-9067035-B2 Drying substances, preparation and use thereof ORIDION MEDICAL (1987) LTD. (IL) 2015-06-30 US disclosed
US-20140230652-A1 DRYING SUBSTANCES, PREPARATION AND USE THEREOF ORIDION MEDICAL (1987) LTD. (IL) 2014-08-21 US disclosed
US-8764888-B2 Drying substances, preparation and use thereof ORIDION MEDICAL 1987 LTD. (IL) 2014-07-01 US disclosed
US-8747752-B2 Drying substances, preparation and use thereof ORIDION MEDICAL (1987) LTD. (IL) 2014-06-10 US disclosed
WO-2014055768-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2014-04-10 WO disclosed
US-20130338523-A1 DRYING SUBSTANCES, PREPARATION AND USE THEREOF ORIDION MEDICAL (1987) LTD. (IL) 2013-12-19 US disclosed
EP-2666795-A1 Drying substances, preparation and use thereof Oridion Medical 1987 Ltd. (IL) 2013-11-27 EP disclosed
US-8540806-B2 Drying substances, preparation and use thereof ORIDION MEDICAL (1987) LTD. (IL) 2013-09-24 US disclosed
US-20130116589-A1 DRYING SUBSTANCES, PREPARATION AND USE THEREOF ORIDION MEDICAL (1987) LTD. (IL) 2013-05-09 US disclosed
US-8366811-B2 Drying substances, preparation and use thereof ORIDION MEDICAL (1987) LTD. (IL) 2013-02-05 US disclosed
US-20120202794-A1 COMPOUNDS PHARMASSET, INC. (US) 2012-08-09 US disclosed
WO-2012103113-A1 PYRAZINE AND IMIDAZOLIDINE DERIVATIVES AND THEIR USES TO TREAT HEPATITIS C GILEAD PHARMASSET, LLC (US) 2012-08-02 WO disclosed
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) 2012-04-12 US disclosed
US-20110172442-A1 AMINO ACID DERIVATIVE NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2011-07-14 US disclosed
US-7902330-B2 Protein kinase inhibitors and methods for identifying same ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2011-03-08 US disclosed
EP-1956054-B1 Phase change ink XEROX CORP (US) 2010-11-24 EP disclosed
US-7838543-B2 Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles ELI LILLY AND COMPANY (US) 2010-11-23 US disclosed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 WO disclosed
US-20100226824-A1 Drying substances, preparation and use thereof ORIDION MEDICAL (1987) LTD. (IL) 2010-09-09 US disclosed
US-20100224066-A1 Drying substances, preparation and use thereof ORIDION MEDICAL (1987) LTD. (IL) 2010-09-09 US disclosed
US-20100226823-A1 Drying substances, preparation and use thereof ORIDION MEDICAL (1987) LTD. (IL) 2010-09-09 US disclosed
EP-2226192-A1 Drying substances, preparation and use thereof Oridion Medical 1987 Ltd. (IL) 2010-09-08 EP disclosed
EP-2226116-A2 Drying substances, preparation and use thereof Oridion Medical 1987 Ltd. (IL) 2010-09-08 EP disclosed
EP-2226341-A2 Drying substances, preparation and use thereof Oridion Medical 1987 Ltd. (IL) 2010-09-08 EP disclosed
US-20100221398-A1 PRESERVATIVE DSM IP ASSETS B.V. (NL) 2010-09-02 US disclosed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 US disclosed
US-7709479-B1 Quinazoline derivatives and their use as pharmaceuticals ASTRAZENECA (SE) 2010-05-04 US disclosed
US-7604746-B2 high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers MCMASTER UNIVERSITY (CA) 2009-10-20 US disclosed
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-07-02 US disclosed
US-20090092975-A1 SELECTABLE MARKER MOLOGIC LTD (GB) 2009-04-09 US disclosed
EP-1337517-B1 PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 2008-11-26 EP disclosed
EP-1958993-A1 Phase change inks containing colorant compounds Xerox Corporation (US) 2008-08-20 EP disclosed
EP-1956054-A2 Colorant compounds Xerox Corporation (US) 2008-08-13 EP disclosed
EP-1828177-B1 NOVEL MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-08-13 EP disclosed
US-20080187664-A1 Phase change inks containing colorant compounds XEROX CORPORATION 2008-08-07 US disclosed
US-20080184910-A1 Mixture of basic dye and wax XEROX CORPORATION 2008-08-07 US disclosed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 US disclosed
US-20070254312-A1 Protein Kinase Inhibitors and Methods for Identiying Same NATIONAL INSTITUTES OF HEALTH 2007-11-01 US disclosed
EP-1747059-A1 PERVAPORATION COMPOSITE MEMBRANES McMaster University (CA) 2007-01-31 EP disclosed
US-7050684-B2 Composition comprising fluorinated, radiation-curable dyes for surface energy control ALCATEL (FR) 2006-05-23 US disclosed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US disclosed
US-7002020-B1 Oxazolidinone combinatorial libraries, compositions and methods of preparation PHARMACIA & UPJOHN COMPANY (US) 2006-02-21 US disclosed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US disclosed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US disclosed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US disclosed
US-20060000778-A1 high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers MCMASTER UNIVERSITY (CA) 2006-01-05 US disclosed
EP-1375527-B1 Composition comprising flourinated, radiation-curable dyes for surface energy control DRAKA COMTEQ BV (NL) 2005-12-14 EP disclosed
WO-2005102503-A1 PERVAPORATION COMPOSITE MEMBRANES MCMASTER UNIVERSITY (CA) 2005-11-03 WO disclosed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US disclosed
US-20050154078-A1 Composition comprising fluorinated, radiation-curable dyes for surface energy control ALCATEL 2005-07-14 US disclosed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US disclosed
US-6844373-B2 Composition comprising fluorinated, radiation-curable dyes for surface energy control ALCATEL (FR) 2005-01-18 US disclosed
US-20050004174-A1 Antibacterial agents GORDEEV MIKHAIL F (US) 2005-01-06 US disclosed
EP-1375527-A2 Composition comprising flourinated, radiation-curable dyes for surface energy control ALCATEL (FR) 2004-01-02 EP disclosed
US-20030225178-A1 Composition comprising fluorinated, radiation-curable dyes for surface energy control ALCATEL 2003-12-04 US disclosed
US-6562844-B2 Attaching an olefin to a solid support; oxidizing the olefin to provide an epoxide functionality; opening the epoxide with an amine to form an amino alcohol; cyclizing the amino alcohol using a phosgene equivalent PHARMACIA & UPJOHN COMPANY 2003-05-13 US disclosed
US-6531470-B1 Antimicrobial compounds PHARMACIA & UPJOHN COMPANY 2003-03-11 US disclosed
EP-1218354-A1 QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS AstraZeneca AB (SE) 2002-07-03 EP disclosed
US-6239152-B1 Oxazolidinone combinatorial libraries, compositions and methods of preparation PHARMACIA & UPJOHN COMPANY 2001-05-29 US disclosed
WO-2001021596-A1 QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS ASTRAZENECA AB (SE) 2001-03-29 WO disclosed
WO-2001021596-A1 QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS ASTRAZENECA AB (SE) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172442-A1 AMINO ACID DERIVATIVE OPRL1, OPRK1, SLC1A1 MIF 1123/4885ALDH1A1 1288/4885CA1 2129/4885
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS MIF 3696/4885ALDH1A1 3087/4885CA1 4047/4885
US-20070254312-A1 Protein Kinase Inhibitors and Methods for Identiying Same PRKCA, PRKCE, PRKCB MIF 3563/4885ALDH1A1 4408/4885CA1 3416/4885
US-20120202794-A1 COMPOUNDS HAVCR2, MAVS, GOT2 MIF 2503/4885ALDH1A1 253/4885CA1 4880/4885
US-12551555-B2 Compositions and methods for potentiating immune activity PTPRCAP, PTPN2, PTPRC MIF 1653/4885ALDH1A1 4675/4885CA1 1546/4885
US-20090092975-A1 SELECTABLE MARKER AMD1, PADI1, PSAT1 MIF 3264/4885ALDH1A1 46/4885CA1 1133/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS MIF 3696/4885ALDH1A1 3087/4885CA1 4047/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 MIF 1734/4885ALDH1A1 1569/4885CA1 102/4885
US-20230044323-A1 COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY NFATC1, MYD88, ICOS MIF 311/4885ALDH1A1 4200/4885CA1 972/4885
US-20100221398-A1 PRESERVATIVE C9, AOX1, MANBA MIF 217/4885ALDH1A1 35/4885CA1 2015/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 MIF 1696/4885ALDH1A1 1723/4885CA1 139/4885
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R MIF 1837/4885ALDH1A1 1529/4885CA1 4638/4885
US-20150239931-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTP4A2, PTPRF, PTPA MIF 3097/4885ALDH1A1 4226/4885CA1 4070/4885
US-20050004174-A1 Antibacterial agents PAICS, OXA1L, PNKP MIF 286/4885ALDH1A1 1632/4885CA1 2908/4885
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS MIF 3696/4885ALDH1A1 3087/4885CA1 4047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.